Hemostemix Inc. (CVE:HEM – Get Free Report) dropped 17.1% during mid-day trading on Thursday . The stock traded as low as C$0.28 and last traded at C$0.32. Approximately 684,632 shares were traded during mid-day trading, an increase of 2% from the average daily volume of 673,865 shares. The stock had previously closed at C$0.38.
Hemostemix Price Performance
The company’s fifty day moving average price is C$0.15 and its 200 day moving average price is C$0.10. The company has a market cap of C$27.44 million, a PE ratio of -15.75 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Kimberly-Clark: A Regal Opportunity in This Dividend King
- What is the Euro STOXX 50 Index?
- 5 Stocks With Above-Market Yields Just Raised Payments Further
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Arista Networks’ Stock Plunge: Buying Opportunity for Investors?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
